LUCID DIAGNOSTICS INC (LUCD) Stock Price & Overview

NASDAQ:LUCD • US54948X1090

1.4 USD
0 (0%)
At close: Mar 6, 2026
1.3755 USD
-0.02 (-1.75%)
After Hours: 3/6/2026, 8:00:00 PM

The current stock price of LUCD is 1.4 USD. Today LUCD is down by 0%. In the past month the price increased by 21.74%. In the past year, price increased by 0.72%.

LUCD Key Statistics

52-Week Range0.9495 - 1.8
Current LUCD stock price positioned within its 52-week range.
1-Month Range1.15 - 1.5
Current LUCD stock price positioned within its 1-month range.
Market Cap
183.288M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.88
Dividend Yield
N/A

LUCD Stock Performance

Today
0%
1 Week
-2.78%
1 Month
+21.74%
3 Months
+35.92%
Longer-term
6 Months +2.19%
1 Year +0.72%
2 Years +72.86%
3 Years N/A
5 Years N/A
10 Years N/A

LUCD Stock Chart

LUCID DIAGNOSTICS INC / LUCD Daily stock chart

LUCD Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to LUCD. When comparing the yearly performance of all stocks, LUCD is one of the better performing stocks in the market, outperforming 80.57% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
LUCD Full Technical Analysis Report

LUCD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LUCD. Both the profitability and financial health of LUCD have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LUCD Full Fundamental Analysis Report

LUCD Earnings

On November 12, 2025 LUCD reported an EPS of -0.1 and a revenue of 1.21M. The company beat EPS expectations (11.04% surprise) and missed revenue expectations (-12.5% surprise).

Next Earnings DateMar 23, 2026
Last Earnings DateNov 12, 2025
PeriodQ3 / 2025
EPS Reported-$0.10
Revenue Reported1.211M
EPS Surprise 11.04%
Revenue Surprise -12.50%
LUCD Earnings History

LUCD Forecast & Estimates

12 analysts have analysed LUCD and the average price target is 3.87 USD. This implies a price increase of 176.25% is expected in the next year compared to the current price of 1.4.

For the next year, analysts expect an EPS growth of 34.33% and a revenue growth 0.54% for LUCD


Analysts
Analysts83.33
Price Target3.87 (176.43%)
EPS Next Y34.33%
Revenue Next Year0.54%
LUCD Forecast & Estimates

LUCD Groups

Sector & Classification

LUCD Financial Highlights

Over the last trailing twelve months LUCD reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 22.12% compared to the year before.


Income Statements
Revenue(TTM)4.40M
Net Income(TTM)-65.84M
Industry RankSector Rank
PM (TTM) N/A
ROA -123.77%
ROE -254.86%
Debt/Equity 0.86
Chartmill High Growth Momentum
EPS Q2Q%60%
Sales Q2Q%3.33%
EPS 1Y (TTM)22.12%
Revenue 1Y (TTM)5.01%
LUCD financials

LUCD Ownership

Ownership
Inst Owners25.56%
Shares130.92M
Float80.22M
Ins Owners9.08%
Short Float %8.58%
Short Ratio4.93
LUCD Ownership

LUCD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.07190.38B
ISRG INTUITIVE SURGICAL INC47.96174.071B
SYK STRYKER CORP24.1139.513B
BSX BOSTON SCIENTIFIC CORP20.4105.876B
IDXX IDEXX LABORATORIES INC41.0448.442B
BDX BECTON DICKINSON AND CO12.2647.586B
EW EDWARDS LIFESCIENCES CORP27.4647.376B
RMD RESMED INC20.5936.838B
GEHC GE HEALTHCARE TECHNOLOGY14.3733.849B
DXCM DEXCOM INC26.7926.209B
ZBH ZIMMER BIOMET HOLDINGS INC11.118.413B
HOLX HOLOGIC INC15.4316.908B
PODD INSULET CORP36.6616.686B

About LUCD

Company Profile

LUCD logo image Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

Company Info

LUCID DIAGNOSTICS INC

360 Madison Avenue, 25th Floor

New York City NEW YORK US

Employees: 70

LUCD Company Website

LUCD Investor Relations

Phone: 12129494319

LUCID DIAGNOSTICS INC / LUCD FAQ

What does LUCD do?

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.


Can you provide the latest stock price for LUCID DIAGNOSTICS INC?

The current stock price of LUCD is 1.4 USD.


Does LUCD stock pay dividends?

LUCD does not pay a dividend.


How is the ChartMill rating for LUCID DIAGNOSTICS INC?

LUCD has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What do analysts say about LUCID DIAGNOSTICS INC (LUCD) stock?

12 analysts have analysed LUCD and the average price target is 3.87 USD. This implies a price increase of 176.25% is expected in the next year compared to the current price of 1.4.


What sector and industry does LUCID DIAGNOSTICS INC belong to?

LUCID DIAGNOSTICS INC (LUCD) operates in the Health Care sector and the Health Care Equipment & Supplies industry.